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Objective:Highhomocysteine level is a risk factor for atherosclerosis andhas been associatedwith lacunar
infarcts (LIs), white matter lesions (WML) and cognitive dysfunction. It is unclear whether homocysteine
is associated with cerebral small vessel disease (cSVD) on top of pre-existent atherosclerosis. We eval-
uated the association between homocysteine and cSVD in a large cohort of patients with symptomatic
atherosclerotic disease.
Methods: Within the SMART-MR study, a prospective cohort study of patients with symptomatic
atherosclerotic disease, we estimated cross-sectional associations of total plasma homocysteine (THCY)
and hyperhomocysteinemia (HHCY) with WML volume and presence of LI, using automated brain seg-
mentation in MRIs of 1232 patients and cognitive function in 763 patients. WML were expressed as a
logarithmic transformed percentage of total brain volume.omocysteine
erebrovascular disease
Results: Linear regression analyses adjusted for age, sex, vascular risk factors and extent of atherosclerosis
showed that THCY and HHCY were signiﬁcantly associated with larger WML volumes (B=0.01%: 95% CI
0.002–0.02%, and B=0.21%: 95% CI 0.04–0.39%). Increasing THCY was signiﬁcantly associated with an
increased risk of LIs (OR 1.04, 95% CI 1.01–1.07, per 1mol). Moreover, HHCYwas associated with worse
cognitive function (B=−0.12: 95% CI −0.22 to −0.01).
ith sy
volumConclusion: In patients w
ciated with higher WML
. Introduction
In cerebral small vessel disease (cSVD), ischemic lesions are
ocated in the supplying areas of the small perforating arteries in
he basal ganglia or deep white matter of the brain. On magnetic
esonance imaging (MRI),markers of cSVDare visible aswhitemat-
er lesions (WML) and lacunar infarcts (LIs). Patients with cSVD
ave a relatively high risk of developing stroke, cognitive impair-
ent and gait disturbances [1,2], and therefore much research has
ocused on identifying modiﬁable risk factors. Both macrovascular
isease, such as atherosclerosis and hypertension, and microvas-
ular disease, such as endothelial dysfunction and leakage of the
lood–brain barrier, are associatedwith cSVD [1–4]. Being involved
n both macro- and microvascular pathways, an important risk
actormay be homocysteine, an amino-acid formedduringmethio-
ine metabolism. It is of particular interest because homocysteine
∗ Corresponding author at: University Medical Center Utrecht, Julius Center for
ealth Sciences andPrimaryCare, Stratenum6.131, POBOX85500, 3508GAUtrecht,
he Netherlands. Tel.: +31 088 7559394; fax: +31 088 7555485.
E-mail address: m.geerlings@umcutrecht.nl (M.I. Geerlings).
1 On behalf of the SMART Study Group.
021-9150 © 2011 Elsevier Ireland Ltd. 
oi:10.1016/j.atherosclerosis.2011.02.027
Open access under the Elsevier OA license.mptomatic atherosclerotic disease, higher homocysteine levels are asso-
e, presence of LI and slightly worse cognitive function.
© 2011 Elsevier Ireland Ltd. 
levels can be regulated by folic acid, vitamin B6 and B12 and could
therefore be a potential target for therapy [5]. Although the results
of lowering homocysteine levels in several large randomized tri-
als have not been encouraging in populations with macrovascular
disease, a closer look at the data suggests that there may well
be an effect in patients with stroke, especially those with cSVD
[5,6]. Homocysteine is largely known for its role in the devel-
opment of atherosclerotic disease, but it is also associated with
cSVD andwith cognitive dysfunction [7–15]. It is unknown towhat
extent homocysteine is associated with cSVD and cognitive func-
tion when atherosclerosis is already present. The objective of this
study was to evaluate the association of homocysteine with WML,
LIs and cognitive function in a cohort of patients with symptomatic
atherosclerotic disease, in order to determine the effect of homo-
cysteine on top of pre-existent atherosclerosis, while accounting
for IMT variation within this cohort.
2. Methods
Open access under the Elsevier OA license.2.1. Study population
Patients were from the Second Manifestations of ARTerial
disease-Magnetic Resonance (SMART-MR) study, a prospective
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ohort study to investigate brain changes on MRI in indepen-
ently living patients with symptomatic atherosclerotic disease.
etails of the design and patients have been described elsewhere
16]. In brief, between May 2001 and December 2005, all patients
ewly referred to the UniversityMedical Center Utrecht withman-
fest coronary artery disease, cerebrovascular disease, peripheral
rterial disease or an abdominal aortic aneurysm (AAA), and with-
ut MR contraindications were invited to participate. Coronary
rterydiseasewasdeﬁnedasmyocardial infarction, coronaryartery
ypass graft surgery or percutaneous transluminal coronary angio-
lasty in the past or at inclusion. Patients with a transient ischemic
ttack or stroke at inclusion and patients who reported stroke in
he past were considered to have cerebrovascular disease. Periph-
ral arterial disease was deﬁned as surgery or angioplasty of the
rteries supplying the lower extremities in history or intermittent
laudication or rest pain at inclusion. AAA was deﬁned as present
AA (distal aortic diameter ≥3 cm) or previous AAA surgery. Dur-
ng a 1-day visit to our medical center, an MRI of the brain was
erformed, in addition to a physical examination, ultrasonography
f the carotid arteries, and blood and urine sampling. Risk factors
ndmedical history were assessedwith questionnaires. Neuropsy-
hological testing was introduced in the SMART-MR study starting
n January 2003 and was performed on the same day as the MRI
nd other investigations. The SMART-MR study was approved by
he ethics committee of the University Medical Center Utrecht and
ritten informed consent was obtained from all participants.
.2. Magnetic resonance imaging protocol
The MR investigations were performed on a 1.5-T whole-
ody system (Gyroscan ACS-NT, Philips Medical Systems, Best,
he Netherlands). The protocol consisted of a transversal T1-
eighted gradient-echo sequence (repetition time (TR)/echo time
TE): 235/2ms), T2-weighted turbo spin-echo sequence (TR/TE:
200/11ms and 2200/100ms), T2-weighted ﬂuid attenuating
nverse recovery (FLAIR) sequence (TR/TE/inversion time (TI):
000/100/2000ms) and an inversion recovery (IR) sequence
TR/TE/TI: 2900/22/410ms) (ﬁeld of view 230mm×230mm;
atrix size, 180×256; slice thickness, 4.0mm; no gap, 38 slices).
.3. Brain segmentation
Weused the T1-weighted gradient-echo, IR and FLAIR sequence
or brain segmentation [17]. The segmentation program distin-
uishes cortical gray matter, white matter, sulcal and ventricular
erebrospinal ﬂuid (CSF), andWML. The segmentation analysiswas
isually checked for the presence of infarcts and adapted if neces-
ary. Total brain volume was calculated by summing the volumes
f gray andwhitematter and, if present,WML volume and infarcts.
ll volumes cranial to the foramen magnum were included. Thus,
he total brain volume includes cerebrum, brainstem and cerebel-
um. Total intracranial volume (ICV) was calculated by summing
he total brain volume and volumes of the sulcal and ventricular
SF. In 188 patients the IR and T1-weighted sequenceweremissing
ue to a temporary change in MRI protocol, and the segmentation
as basedon the FLAIR sequence. Intraclass correlation coefﬁcients
etween segmentation using all 3 sequences and FLAIR only based
n a subset of 740 patients were 0.995, 0.996, 0.961, 0.996, and
.985 for ICV, total brain volume, CSF, ventricular volume, andWML
olume, respectively..4. Infarcts and white matter lesions
Infarcts were rated by two trained investigators and a neuro-
adiologist, blinded to clinical information, and re-evaluated in aerosis 216 (2011) 461–466
consensus meeting. Infarcts were deﬁned as focal hyperintensities
on T2-weighted images of at least 3mm in diameter. Hyperinten-
sities located in the white matter also had to be hypointense on
T1-weighted and FLAIR images to distinguish them from WML.
Dilated perivascular spaceswere distinguished from infarcts on the
basis of their location, form and absence of gliosis. Brain infarcts
were categorized as cortical infarcts, lacunar infarcts, large subcor-
tical infarcts and infratentorial infarcts. We deﬁned LIs as infarcts
of 3–15mm in diameter and located in the subcortical white mat-
ter, thalamus or basal ganglia. Silent lacunes were deﬁned as LIs
in patients with no history of cerebrovascular disease. Large sub-
cortical infarcts were sized >15mm and were not conﬂuent with
cortical infarcts. Infratentorial infarcts were located in the brain-
stem or cerebellum. Volumes of totalWMLwere expressed relative
to ICV (%).
2.5. Neuropsychological assessment
Cognitive functioning was assessed with a set of standard
neuropsychological tests, sensitive to mild impairments. Verbal
memory was assessed with 5 consecutive trials of the 15-word
learning test (a modiﬁcation of the Rey Auditory Verbal Learn-
ing test). Immediate recall and delayed recall were assessed.
Non-verbal memory was assessed using the delayed recall of the
Rey–Osterrieth Complex Figure test. Executive functioning was
assessed with three tests. The Visual Elevator test (subtest of the
Test of Everyday Attention is a timed test of 10 trials that measures
mental ﬂexibility and shifting of attention). The Brixton Spatial
Anticipation test was used to assess the capacity to discover log-
ical rules and mental inhibition and ﬂexibility. The total number
of errors was recorded. The Verbal Fluency test (letter A, 1min
time frame) was used to assess mental ﬂexibility and employ-
ment of strategies. We calculated a composite z-score composed
of the mean z-scores of 5 different cognitive tests. Before calculat-
ing the z-scores, the scores of the Visual Elevator test and Brixton
Spatial Anticipation test were inversed, so that lower scores rep-
resented poorer performance. Premorbid intellectual functioning
was assessedbyusing theDutchversionof theNationalAdult Read-
ing Test (DART) in which patients read aloud a list of words with
irregular pronunciation [18]. For details of the neuropsychological
tests used, we refer to Lezak et al. [19].
2.6. Homocysteine and vascular risk factors
An overnight fasting venous blood sample was taken to deter-
mine glucose, creatinine, lipid and total plasma homocysteine
levels (THCY). Hyperhomocysteinemia was deﬁned according to
sex-speciﬁc 95th percentiles studied by van der Griend et al. as
a fasting THcy level of 16.3mol/L or greater in women and
18.8mol/L or greater inmen [20]. These95th-percentile reference
values are similar to values in other Dutch populations. [21,22].
Height andweight weremeasured and bodymass index (BMI) was
calculated (kg/m2). Systolic and diastolic blood pressures (mmHg)
were measured twice with a sphygmomanometer and the average
of the twomeasures was calculated. Diabetes mellitus was deﬁned
asahistoryofdiabetes, glucose level of≥7.0mmol/Lor self reported
use of oral antidiabetic drugs or insulin. Estimated glomerular
ﬁltration rate (eGFR) was computedwith the Cockroft–Gault equa-
tion [23]. Smoking was assessed with packyears and alcohol intake
was categorized as never, former, or current. Patients who had quit
smoking or drinking during the past year were classiﬁed as cur-
rent smoker or alcohol intake. Ultrasonography was performed to
measure the intima-media thickness (IMT) (mm) in the left and
right common carotid arteries, represented by the mean value of
six measurements.
erosclerosis 216 (2011) 461–466 463
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Table 1
Baseline characteristics of the study sample (n=1223) according to the presence or
absence of hyperhomocysteinemia.
Risk factor Hyperhomocys-
teinemia
(n=163)
No hyperhomocys-
teinemia
(n=1060)
Age (years) 62.6 (10.7) 58.0 (9.9)
Male (%) 72.4 80.5
Vascular
BMI (kg/m2) 26.4 (3.9) 26.9 (3.8)
Smoking (packyears)a 21.2 (0–57.4) 18.9 (0–49)
Present alcohol use (%) 66.7 76.2
Hypertension (%) 57.1 51
Cholesterol (mmol/L) 5.2 (1.2) 4.9 (1.0)
Diabetes (%) 21.3 20.4
Macrovascular disease
Cerebrovascular disease (%) 27.6 22.5
Peripheral artery disease (%) 25.2 21.3
Coronary artery disease (%) 49.7 60.6
Carotid IMT (mm) 1.0 (0.3) 0.9 (0.3)
with HHCY or higher levels of THCY had a higher risk of hav-
T
A
U
i
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.7. Study sample
Of the 1309 patients included in the SMART-MR study, 86
atients were excluded from the analyses, because of irretrievable
R data (n=19), missing FLAIR images (n=14), artefacts (n=44)
r missing homocysteine levels (n=9). Thus, the analytical sam-
le consisted of 1223 patients. Of these 1223 patients, 763 patients
ompleted cognitive testing.
.8. Data analysis
The relation between homocysteine and cSVD was evaluated
sing linear regression analysis with both the continuous variable
THCY) and dichotomous deﬁnition (HHCY) as determinant and the
atural log transformed relativeWML volume as outcome variable.
ogistic regression was used to examine severe WML load deﬁned
s the highest quintile of WML. Furthermore, logistic regression
as used to examine the association of homocysteine and pres-
nce of LI. The ﬁrst model adjusted for age and sex, and the second
odel additionally for hypertension, alcohol intake, BMI, choles-
erol level, diabetes, smoking, serum creatinine level, history of
oronary artery disease, peripheral artery disease and cerebrovas-
ular disease. Inmodel 3 IMTwas added.We repeated the analyses
fter excluding patients with a history of cerebrovascular disease.
ince the effect of homocysteine could be different in mid-life and
ate-life, we tested the interaction between age (on a continuous
cale) and homocysteine level (on a continuous scale). If statisti-
ally signiﬁcant, we stratiﬁed the population in patients younger
han 65years and patients 65years or older.
The relation between homocysteine and cognitive function was
valuated using linear regression analysis with THCY and HHCY
s the determinant and a composite z-score of all cognitive tests
s the outcome variable. The ﬁrst model adjusted for age, sex and
remorbid intelligence as estimated by the DART. Additionally, we
djusted for the natural log transformed relative WML volume to
ee whether this association was driven by WML volume.
. Results
Themean age of the study population was 59years (SD 10). The
ean THCY was 14.13mol/L (SD 6.41) for men and 12.65mol/L
SD 4.71) for women. Mean THCY was higher in patients with 2
r more types of atherosclerotic disease (15.3±6.8mol/L) com-
ared with 1 type (13.5±5.8mol/L). 15.4% of the patients had
HCY. The median WML volume was 1.53ml (10th–90th per-
able 2
ssociation of homocysteine levels with small vessel disease markers.
White matter lesion volumea
Regression coefﬁcient (95% CI)
Hyperhomocysteinemia (yes/no)
Model 1 0.30 (0.12–0.47)***
Model 2 0.21 (0.04–0.39)*
Model 3 0.21 (0.04–0.39)*
Homocysteine level (per 1mol/L increase)
Model 1 0.02 (0.01–0.03)***
Model 2 0.01 (0.002–0.02)*
Model 3 0.01 (0.002–0.02)*
nstandardized regression coefﬁcients B or Odds ratios with 95% conﬁdence intervals (CI
n men.
a Natural log of WML as percentage of ICV.
b Deﬁned as highest quintile of WML volume. Model 1: adjusted for age, sex. Model 2:
holesterol level, smoking, alcohol use, eGFR, cerebrovascular disease, coronary disease, p
* p<0.05.
** p<0.005.
*** p<0.001.Values are in means (SD).
a Median (10–90% range).
centile: 0.45–7.66) in the total population and 7.65ml (10th–90th
percentile: 4.61–23.35) in the severe WML group. Patients with
HHCY were older, were more often female, smoked more, had
higher cholesterol levels and were more likely to have coronary
artery disease (Table 1). Of the study sample, 19.5% had two or
more types of macrovascular disease. Homocysteine levels were
higher in patients with 2 or more types of macrovascular disease
(15.3±6.8mol/L) compared with 1 type (13.5±5.8mol/L).
3.1. White matter lesions
HHCY aswell as increasing levels of THCY (permol/L increase)
were associated with greater WML volume after adjusting for age
and sex (Bs: 0.30%, 95%CI 0.12–0.47,p<0.001and0.02% (0.01–0.03)
(p<0.001)), respectively. Additional adjustment for multiple vas-
cular risk factors, kidney function and atherosclerotic disease
only slightly changed the associations (Table 2). Also, patientsing severe WML which remained after adjusting for all covariates
(Table 2). After excluding patients with cerebrovascular disease,
the adjusted associations between homocysteine levels and WML
volume remained statistically signiﬁcant, albeit a little less strong.
Adjusting for IMT did not change the results.
Severe white matter lesionsb Presence of lacunar infarcts
Odds ratio (95% CI) Odds ratio (95% CI)
1.8 (1.2–2.7)* 1.5 (0.97–2.2)
1.6 (1.0–2.5)* 1.4 (0.9–2.3)
1.6 (1.0–2.5)* 1.4 (0.8–2.2)
1.03 (1.01–1.05)* 1.04 (1.02–1.07)***
1.02 (0.99–1.04) 1.04 (1.02–1.07)***
1.02 (0.99–1.04) 1.04 (1.01–1.07)**
). Hyperhomocysteinemia is deﬁned as ≥16.3mol/L in women and ≥18.8mol/L
model 1 + systolic blood pressure, diastolic blood pressure, diabetes mellitus, BMI,
eripheral artery disease. Model 3: Model 2 + IMT.
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Table 3
Associations between homocysteine and small vessel disease markers, stratiﬁed for age.
White matter lesion volumea Severe white matter lesionsb Presence of lacunar infarcts
Regression coefﬁcient (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
<65years >65years <65years >65years <65years >65years
Hyperhomocysteinemia (yes/no)
Model 1 −0.04 (−0.25–0.17) 0.66 (0.33–0.99)*** 0.98 (0.45–2.11) 3.1 (1.6–6.1)*** 2.0 (1.0–3.9)* 1.0 (0.5–2.0)
Model 2 −0.04 (−0.26–0.17) 0.64 (0.31–0.97)*** 0.98 (0.46–2.12) 3.0 (1.5–6.0)*** 1.9 (0.98–3.8) 1.0 (0.5–2.0)
Homocysteine level (per 1mol/L increase)
Model 1 0 (−0.01–0.01) 0.04 (0.02–0.06)*** 0.98 (0.94–1.03) 1.08 (1.03–1.14)** 1.06 (1.02–1.1)** 1.03 (0.99–1.07)
Model 2 0 (−0.01–0.01) 0.04 (0.02–0.06)*** 0.98 (0.94–1.03) 1.08 (1.02–1.14)* 1.06 (1.02–1.1)** 1.02 (0.98–1.07)
Unstandardized regression coefﬁcient B or Odds ratios with 95% conﬁdence intervals (CI). Hyperhomocysteinemia is deﬁned as ≥16.3mol/L in women and ≥18.8mol/L
in men.
a Natural log of WML as percentage of ICV.
b Deﬁned as highest quintile of WML volume. Model 1: adjusted for age, sex, systolic blood pressure, diastolic blood pressure, diabetes mellitus, BMI, cholesterol level,
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* p<0.05.
** p<0.005.
*** p<0.001.
.2. Lacunar infarcts
Patients with increasing THCY levels were more likely to have
acunar infarcts (OR 1.04, 95% CI 1.02–1.07, per mol/L, p<0.001),
s were those with HHCY, although this did not reach statistical
igniﬁcance (OR 1.5, 95% CI 0.97–2.2) (Table 2). Furthermore, THCY
evelswere associatedwith silent lacunes (OR1.05; 95%CI 1.02–1.1,
< 0.05, per 1mol/L increase). Adjusting for IMT did not change
he results.
.3. Modifying effect of age on relationships
There was a signiﬁcant interaction between age and homo-
ysteine levels on WML volume (p=0.001). After stratiﬁcation,
ssociations between HHCY and WML volume were stronger in
atients 65years or older (B=0.66; 95% CI 0.33–0.99, p<0.001),
hereas in patients younger than 65years of age the association
isappeared (B=−0.04; 95% CI −0.25–0.17). Similar results were
ound for THCY and WML volume (Table 3). In the older age group
HCYwasassociatedwithanORof3.1 (95%CI1.6–6.1,p<0.001) for
evereWML, comparedwith anOR of 0.98 (95% CI 0.45–2.12) in the
ounger agegroup. The results for LIswere theoppositewithno sig-
iﬁcant association in theolder age groupand stronger associations
n the younger age group.
.4. Cognitive functionAs can be seen in Table 4, patients with higher levels of homo-
ysteine or HHCYhad slightly lower cognitive z-scores (per 1mol,
=−0.01; 95% CI −0.02 to −0.01, p<0.001). These associations did
ot change after adjustment for co-existent WML volume.
able 4
ssociation of homocysteine levels with composite z-score of cognitive tests
n=763).
Composite z-score
Regression coefﬁcient (95% CI)
Hyperhomocysteinemia (yes/no)
Model 1 −0.13 (−0.24 to −0.03)*
Model 2 −0.12 (−0.22 to −0.01)*
Homocysteine level (per 1mol/L increase)
Model 1 −0.01 (−0.02 to −0.01)**
Model 2 −0.01 (−0.02 to −0.01)**
nstandardized regression coefﬁcient B with 95% conﬁdence intervals (CI). Model
adjusted for age, sex and premorbid IQ, model 2 additionally adjusted for WML
olume.
* p<0.05.
** p<0.001.isease. Model 2: model 1 + IMT.
4. Discussion
In this cohort of patients with symptomatic atherosclerotic
disease, higher homocysteine levels were associated with larger
WML volume and a greater risk of having LIs, including silent
LIs. The association with WML was particularly strong in patients
over 65years, whereas the association with lacunar infarcts was
stronger in younger patients. Moreover, increasing homocysteine
levels were associated with slightly worse cognitive function, but
were not explained or mediated by WML.
Strengths and limitations of this study are as follows. Our cohort
enabled us to examine the association of homocysteine with cSVD
and cognition in patients with background atherosclerotic disease.
Moreover, the use of automated volumetric measurements greatly
enhances the reliability of WML volume readings. A limitation is
the cross-sectional design, which precludes any conclusion about
a possible causal relationship. Also, we did not measure folic acid
and vitamin B levels and therefore have no information on possible
low (treatable) vitamin levels.
Our results are in line with previously reported associations
of high homocysteine levels with WML volume in the general
elderly population [8,11,14]. The scarce data on LI show signiﬁ-
cantly higher levels of homocysteine in patients with LIs compared
with those without [8,23]. The present study conﬁrms this rela-
tionship: for each 1mol increase in THCY, the risk of LIs increased
by 4%. The size of associations between homocysteine levels and
markers of cSVD are comparable with studies concerning healthy
persons without atherosclerosis, suggesting that pathways other
than atherosclerotic (macrovascular) disease are responsible for
the development of cSVD, in which homocysteine may play a role.
Pathophysiological pathways may involve microvascular disease
through endothelial dysfunction or even direct neurotoxicity [24].
The associations between homocysteine and WML were
stronger in patients older than 65years. The pathologic correlates
of WML include ependymal and matrix changes, inﬂammation,
demyelinisation, chronic ischemia and endothelial dysfunction
[25,26]. Age and vascular burden can increase ependymal and
matrix changes, vascular inﬂammation and ischemia. Homocys-
teine has a direct toxic effect on the endothelium [24]. The
interaction of homocysteine with age might suggest that age and
pathological changes in WML may create a vulnerability of the
endothelium, in which it is more sensitive for additional damage,
such as the toxic effect of homocysteine, resulting in endothelial
dysfunction. As such, previous damage reinforces the probability
of consequent damage. This view is supported by longitudinal evi-
dence, showing that age and baseline WML load are the strongest
predictors for WML progression [27]. Moreover, leakage of the
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lood–brain barrier and endothelial dysfunction have been noted
n patients with extensive WML [3,4]. Remarkably, the associa-
ion between homocysteine and LI was stronger in the younger
ge group. Although we do not have an explanation readily avail-
ble, it could be that the younger patients weremore likely to have
ntered the study with a symptomatic LI than the older patients.
lder patients were more likely to be treated for vascular disease
efore they were included in the study, thereby reducing the risk
o be includedwith a symptomatic LI. If the underlyingmechanism
iffers between occurrence of symptomatic and asymptomatic LIs,
his may have resulted in different associations between homocys-
eine andpresence of LIs between younger and older patients in our
tudy sample. In any case, it underscores thenotion that although LI
ndWML are related, theymay reﬂect two far ends of a continuous
linical phenotype.
The association of higher homocysteine levels with slightly
orse cognitive functioning in our study conﬁrms earlier reported
esults in healthy populations [28,29]. Similar to those stud-
es, the associations found in our study did not change when
djusting for co-existent WML volume, suggesting that cognitive
unctioning is inﬂuenced by other factors than WML seen on MRI.
ther factors that have been proposed are MRI-invisible micro-
ngiopathy and possible direct neurotoxic effect of homocysteine
8,28,29].
There are no data on the effect of lowering homocysteine lev-
ls on progression of WML. Several large randomized trials with
itamin supplements have been conducted in large populations
ith macrovascular disease. Although the results have not been
ncouraging, a closer look at the data suggests that there may well
e an effect in subgroups, especially in patients with stroke [5].
ubgroup analyses of the recently ﬁnished VITATOPS suggested a
isk reduction for the primary endpoint (stroke, myocardial infarc-
ion, or vascular death) in patients with small vessel stroke [6].
hether treatment with supplements can slow the development
fWML and consequently gait disturbances and cognitive dysfunc-
ion, remains to be elucidated and randomized controlled trials
ith repeated MRI measurements are needed. Our results sug-
est that the focus of these trials should be on elderly patients
ith true HHCY, as these patients could beneﬁt most from ther-
py.
In sum, this study shows that homocysteine levels are also
ssociated with higher WML volumes, increased risk for LI and
lightly worse cognitive performance in patients with pre-existent
therosclerotic disease, comparable of that found in the general
opulation. This suggests a role for homocysteine in the association
ith cSVD other than atherosclerotic disease.
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